{
  "docId": "019de077-5087-71ae-b0e8-0abfd1317859",
  "docSlug": "b6fff97596ca7cba1b2ee8405a1dc7cd",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 38 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 38,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a split-panel layout to define the problem (NF1-PN) and the solution (KOMET trial results).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-5087-71ae-b0e8-0abfd1317859/23",
  "deckHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859",
  "deckJsonHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859.json",
  "deckAnchorHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.83
      },
      "kind": "callout",
      "text": "KOMET has the potential to address the high unmet need in adult patients with NF1-PN",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc2a37ea-ec30-444a-950d-faa6ef152b6b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.06,
        "y": 0.55
      },
      "kind": "chart",
      "text": "US 68K, EU5 64K, JP 22K",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c30b1833-1dec-4365-a30c-0ed49892595d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "chart",
      "text": "80% adults, 20% paediatric",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92c1ab1a-ed8f-48b2-93cb-fdadd678953c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.5,
        "x": 0.42,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "Phase III KOMET trial cross over design",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47b025f2-21ee-4597-87f5-39d584471a30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.5,
        "x": 0.42,
        "y": 0.6
      },
      "kind": "list",
      "text": "Primary endpoint met: statistically significant, clinically meaningful tumour volume reduction; encouraging effect across pain severities; low discontinuation rates; rapid efficacy onset",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2281730c-aa85-4629-a550-b317516b3352",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.06,
        "y": 0.35
      },
      "kind": "list",
      "text": "characterised by benign tumours that develop on nerve sheaths; leads to disfigurement, motor dysfunction and pain",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5156add-1ea7-46d1-9a72-f4b780c98e69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.06,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "NF1-PN a progressive, genetic condition",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c94203a-c449-45a2-887f-1cf386c3d08b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Epidemiology data refers to diagnosed patients... 1. KOMET trial allowed cross over to Koselugo before 12 cycles. 1 cycle = 28 days. Collaboration partner: Merck & Co., Inc. (Koselugo). Appendix: Glossary.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d71e7e1-16d7-4b40-ae49-8cfe8fea2c15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Rare Disease – R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a28c85a-713c-4fd5-9244-6a42c640264e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Expanding the potential of Koselugo to adult patients with NF1-PN",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7466449f-d58a-4207-a652-e54ed7d86e80",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "96c7b737-3fdd-4b0b-9eb6-ce2c2cdb1cda",
      "evidence": "The slide contains a list/bullet points highlighting key information about Rare Disease – R&D highlights.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}